Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00729664 | Multiple Ascending Dose (MDX1105-01) | PHASE1 | COMPLETED | 281 | — | — | Feb 1, 2009 | Jul 1, 2015 | Sep 7, 2015 | 11 | United States |
| Arm | Type | Description |
|---|---|---|
| Anti-PDL-1 antibody (Arm 1) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 2) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 3) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 4) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 5) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Name | Type | Description |
|---|---|---|
| Anti-PDL-1 antibody | BIOLOGICAL | Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 * The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pa...